KPRX KIORA PHARMACEUTICALS INC: institutional ownership and insider trading
23 funds reported holding $2.97M of KIORA PHARMACEUTICALS INC in their latest 13F filings; in Q2 2026 funds net bought $2.02M, with 10 new positions and 6 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market.
KPRX revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$2.08M, EPS -0.34
- Quarter ended Mar 31, 2026: revenue n/a, net income −$2.42M, EPS -0.58
- Quarter ended Dec 31, 2025: revenue $0, net income $4.31M, EPS -1.59
- Quarter ended Sep 30, 2025: revenue $0, net income $26.8K, EPS 0.01
Famous investors holding KPRX
- Ken Griffin (Citadel Advisors): $305K, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $234K, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $195K, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $78.4K, 0.0% of the portfolio
Largest institutional holders of KPRX
- PERCEPTIVE ADVISORS LLC — $1.15M
- ADAR1 Capital Management, LLC — $442K
- CITADEL ADVISORS LLC — $305K
- TWO SIGMA INVESTMENTS, LP — $234K
- MILLENNIUM MANAGEMENT LLC — $195K
- HRT FINANCIAL LP — $154K
- RENAISSANCE TECHNOLOGIES LLC — $78.4K
- GEODE CAPITAL MANAGEMENT, LLC — $70.3K
- VANGUARD GROUP INC — $65.2K
- VANGUARD CAPITAL MANAGEMENT LLC — $52.2K
5%+ owners
- Alyeska Investment Group, L.P.: 10.0% (Schedule 13G, filed May 15, 2026)
- Nantahala Capital Management, LLC: 10.0% (Schedule 13G/A, filed Aug 14, 2026)
- Perceptive Advisors LLC: 10.0% (Schedule 13G, filed Aug 10, 2026)
- ADAR1 Capital Management GP, LLC: 9.9% (Schedule 13G/A, filed Aug 14, 2026)
- Baselake Partners, LP: 5.8% (Schedule 13G, filed Sep 17, 2026)